FAM102A

Across TCGA pan-cancer cohorts, FAM102A mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated FAM102A data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher FAM102A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated FAM102A expression acts as an unfavorable survival marker, although some lineages such as UCEC and PDAC show a favorable association.

LSCC, UCEC, and PDAC are the cancer types where FAM102A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Quartile	All	0.548	0.951	<.001	22	view →
UCEC	OS	Median	All	1.000	0.889	.007	8	view →
PDAC	OS	Median	All	0.520	0.314	.025	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

FAM102A–LSCC (DFS)

Open the LSCC breakdown →